As previously reported, Craig-Hallum analyst Adam Vogel initiated coverage of Aclaris Therapeutics (ACRS) with a Buy rating and $10 price target The firm cites a proof-of-concept setup into the second half of 2026 readouts and a valuation that still implies limited credit for ATI-052 ahead of Phase 1b data.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics reports ‘positive’ results from ATI-2138
- Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052
- Aclaris Therapeutics Expands Inflammation and Immunology Pipeline Strategy
- Aclaris advances ATI-052 after positive Phase 1a results
- Aclaris Therapeutics reports ‘positive’ results from Phase 1a trial of ATI-052